Treatment of Pain Associated With Fibromyalgia

November 5, 2020 updated by: Daiichi Sankyo, Inc.

A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated With Fibromyalgia

The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in participants receiving either dose of DS-5565 versus placebo.

Weekly ADPS is based on daily pain scores reported by the subject that best describes his or her worst pain over the previous 24 hours.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

1301

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Argentina
      • Cordoba, Argentina
      • San Miguel de Tucuman, Argentina
      • Santa Fe, Argentina
    • Buenos Aires
      • Caba, Buenos Aires, Argentina
      • La Plata, Buenos Aires, Argentina
      • Lanús, Buenos Aires, Argentina
      • Mar Del Plata, Buenos Aires, Argentina
      • Quilmes, Buenos Aires, Argentina
      • San Fernando, Buenos Aires, Argentina
    • Santa FE
      • Rosario, Santa FE, Argentina
  • Austria
      • Klagenfurt, Austria
      • Senftenberg, Austria, 3541
      • Vienna, Austria, 1090
  • Belarus
      • Minsk, Belarus
      • Vitebsk, Belarus
  • Belgium
      • Brussels, Belgium
      • Edegem, Belgium
      • Gozee, Belgium
      • Oostham, Belgium
  • Chile
      • Antofagasta, Chile
      • Providencia, Chile
      • Puerto Varas, Chile
      • Vina Del Mar, Chile
  • Colombia
      • Barranquilla, Colombia
      • Bogota, Colombia
  • Israel
      • Haifa, Israel
      • Kfar Saba, Israel
      • Ramat Gan, Israel
      • Tel-aviv, Israel
  • Mexico
      • Cuautitlán Izcalli, Mexico
      • Durango, Mexico
      • Guadalajara, Mexico
      • Leon, Mexico
      • Mexico City, Mexico
  • Poland
      • Elblag, Poland
      • Gdansk, Poland
      • Katowice, Poland
      • Kraków, Poland
      • Lublin, Poland
      • Nadarzyn, Poland
      • Nowa Sol, Poland
      • Torun, Poland
      • Tychy, Poland
      • Warsaw, Poland
  • Portugal
      • Aveiro, Portugal
      • Braga, Portugal
      • Guimaraes, Portugal
      • Lisboa, Portugal
      • Ponte de Lima, Portugal
      • Porto, Portugal
      • Vila Nova de Gaia, Portugal
  • Slovenia
      • Ljubljana, Slovenia
      • Slovenj Gradec, Slovenia
  • Spain
      • Alicante, Spain
      • Barcelona, Spain
      • Elche, Spain
      • Granada, Spain
      • Guadalajara, Spain
      • Madrid, Spain
      • Santiago de Compostela, Spain
      • Sevilla, Spain
  • Switzerland
      • Geneva, Switzerland
      • St. Gallen, Switzerland
  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35242
      • Huntsville, Alabama, United States
    • Arizona
      • Phoenix, Arizona, United States, 85020
      • Scottsdale, Arizona, United States
      • Tempe, Arizona, United States
      • Tucson, Arizona, United States
    • California
      • Anaheim, California, United States
      • Covina, California, United States, 91723
      • El Cajon, California, United States, 92020
      • Encino, California, United States
      • Huntington Beach, California, United States, 92646
      • Lakewood, California, United States, 90712
      • Lomita, California, United States, 90717
      • Los Angeles, California, United States
      • National City, California, United States, 91950
      • Northridge, California, United States, 91324
      • Oceanside, California, United States
      • Sacramento, California, United States
      • Upland, California, United States, 91786
      • Walnut Creek, California, United States
    • Florida
      • Boca Raton, Florida, United States, 33486
      • DeLand, Florida, United States, 32720
      • Edgewater, Florida, United States, 32132
      • Fort Lauderdale, Florida, United States
      • Fort Myers, Florida, United States
      • Hialeah, Florida, United States, 33016
      • Largo, Florida, United States, 33774
      • Lauderdale Lakes, Florida, United States, 33319
      • Maitland, Florida, United States
      • Miami, Florida, United States
      • Orlando, Florida, United States, 32807
      • Sunrise, Florida, United States
      • Tamarac, Florida, United States
      • Tampa, Florida, United States
      • Vero Beach, Florida, United States, 32960
      • West Palm Beach, Florida, United States
      • Winter Haven, Florida, United States
      • Winter Park, Florida, United States
    • Georgia
      • Dawsonville, Georgia, United States
      • Marietta, Georgia, United States, 30060
      • Smyrna, Georgia, United States
    • Illinois
      • Chicago, Illinois, United States
    • Indiana
      • Evansville, Indiana, United States
      • Granger, Indiana, United States
    • Kansas
      • Overland Park, Kansas, United States
    • Kentucky
      • Owensboro, Kentucky, United States, 423303
    • Louisiana
      • Lake Charles, Louisiana, United States
      • New Orleans, Louisiana, United States, 70119
    • Maryland
      • Frederick, Maryland, United States
    • Massachusetts
      • Brockton, Massachusetts, United States
      • North Dartmouth, Massachusetts, United States
    • Michigan
      • Ann Arbor, Michigan, United States
      • Ann Arbor, Michigan, United States, 48104
      • Lansing, Michigan, United States
      • Rochester Hills, Michigan, United States
    • Missouri
      • Florissant, Missouri, United States
      • Hazelwood, Missouri, United States
      • O'Fallon, Missouri, United States
    • Nebraska
      • Bellevue, Nebraska, United States
    • New Hampshire
      • Newington, New Hampshire, United States
    • New Mexico
      • Albuquerque, New Mexico, United States
    • New York
      • Brooklyn, New York, United States, 11230
      • Cedarhurst, New York, United States
      • Rochester, New York, United States
    • North Carolina
      • Charlotte, North Carolina, United States
      • Raleigh, North Carolina, United States
      • Winston-Salem, North Carolina, United States
    • North Dakota
      • Minot, North Dakota, United States, 58701
    • Ohio
      • Cincinnati, Ohio, United States
      • Columbus, Ohio, United States
      • Dayton, Ohio, United States
      • Middleburg Heights, Ohio, United States, 44130
    • Oklahoma
      • Oklahoma City, Oklahoma, United States
    • Oregon
      • Portland, Oregon, United States
    • Pennsylvania
      • Altoona, Pennsylvania, United States
      • Media, Pennsylvania, United States
      • Wyomissing, Pennsylvania, United States
    • South Carolina
      • Greenville, South Carolina, United States
      • Mount Pleasant, South Carolina, United States
    • Tennessee
      • Chattanooga, Tennessee, United States, 37421
      • Franklin, Tennessee, United States, 37064
      • Knoxville, Tennessee, United States, 37912
      • Memphis, Tennessee, United States
    • Texas
      • Austin, Texas, United States, 78756
      • Houston, Texas, United States, 77024
      • Lake Jackson, Texas, United States
      • San Antonio, Texas, United States
    • Virginia
      • Norfolk, Virginia, United States
      • Richmond, Virginia, United States, 23235
    • Washington
      • Bellevue, Washington, United States, 98007
      • Richland, Washington, United States, 99352

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age ≥ 18 years
  • Able to give written informed consent
  • Able to complete subject-reported questionnaires per the investigator's judgment
  • At screening, subjects must meet the 1990 American College of Rheumatology (ACR) criteria for FM, i.e. widespread pain present for at least 3 months and pain in at least 11 of 18 specific tender point sites. In addition, the 2010 ACR criteria must be met:
  • Widespread pain index (WPI) ≥ 7 and symptom severity (SS) scale score ≥ 5, or WPI 3 to 6 and SS scale score ≥ 9
  • Symptoms have been present at a similar level for at least 3 months
  • The subject does not have a disorder that would otherwise explain the pain
  • ADPS of ≥ 4 on the 11-point numeric rating scale (NRS) over the past 7 days prior to randomization (based on completion of at least 4 daily pain diaries during the 7-day baseline period prior to randomization)
  • Subject must have documented evidence of a fundoscopic examination (with pupil dilation) within 12 months prior to screening or at screening.
  • Women of child-bearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy during the study and for 4 weeks after study completion.

Exclusion Criteria:

  • Clinically significant unstable neurologic, psychiatric, ophthalmologic, hepatobiliary, respiratory, or hematologic illness or unstable cardiovascular disease (e.g. severe hypotension, uncontrolled cardiac arrhythmia, or myocardial infarction) or any other concurrent disease within 12 months prior to screening that in the opinion of the investigator would interfere with study participation or assessment of safety and tolerability
  • Anticipation of initiation or significant change to normal daily exercise routines or need for ongoing use of concomitant medications or non-pharmacological pain management techniques that may confound assessments of efficacy and/or safety
  • Unable to undergo pre-study washout of prohibited concomitant medications
  • Subjects who are at risk of suicide as defined by their responses to the Columbia-Suicide Severity Rating Scale (C-SSRS) or in the opinion of the investigator. Note: Patients answering "yes" to any of the C-SSRS questions at screening must be excluded. Such patients should be referred immediately to a mental health professional for appropriate evaluation.
  • Current severe or uncontrolled major depressive disorder or anxiety disorders as assessed by the Mini-international Neuropsychiatric Interview (MINI) mild to moderate major depression or anxiety disorders are permitted provided that the investigator assesses the patient as clinically stable and appropriate for entry into the study.
  • Any diagnosis of lifetime bipolar disorder or psychotic disorder
  • Subjects with pain due to other conditions (e.g. diabetic peripheral neuropathic pain or post-herpetic neuralgia) that in the opinion of the investigator, would confound assessment or self-evaluation of the pain associated with FM.
  • Subjects with pain due to any widespread inflammatory musculoskeletal disorder (e.g. rheumatoid arthritis, lupus) or widespread rheumatic disease other than FM.
  • Abuse or dependence of prescription medications, street drugs, or alcohol within the last 1 year
  • Any history of a malignancy other than basal cell carcinoma within the past 5 years
  • A diagnosis of untreated sleep apnea or initiation of treatment for sleep apnea within the past 3 months
  • Pregnancy or breast-feeding, or intent to become pregnant during the study period
  • Subject is currently enrolled in or has not yet completed at least 30 days since ending another investigational device or drug study or is receiving other investigational agents.
  • Known hypersensitivity to alpha2-delta (α2δ) ligands or other components of the study medications. Note: Prior exposure to DS-5565 is allowed, as long as hypersensitivity to DS-5565 was not observed.
  • Subjects who are unlikely to comply with the protocol (e.g. uncooperative attitude, inability to return for subsequent visits) and/or otherwise considered by the investigator to be unlikely to complete the study.
  • Abnormal investigative tests (i.e. electrocardiograms [ECGs]) and laboratory values judged by the investigator to be clinically significant at screening, with particular focus on: a. Abnormal renal function defined as calculated creatinine clearance (CrCl) < 60 mL/min determined by the central laboratory using the modified Cockcroft-Gault equation; blood urea nitrogen> 1.5 × upper limit of normal (ULN); creatine kinase > 3.0 × ULN; serum creatinine > 1.6 mg/dL (> 141.4 μmol/L); b. Abnormal liver function defined as aspartate aminotransferase (AST) > 2.0 × ULN, alanine aminotransferase (ALT) > 2.0 × ULN; alkaline phosphatase > 1.5 × ULN; total bilirubin> 1.2 × ULN. If a subject has total bilirubin > 1.2 ULN, unconjugated and conjugated bilirubin fractions should be analyzed and only subjects documented to have Gilbert's syndrome may be enrolled.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Participants take one each of placebo tablet and capsule, twice daily (BID)
Drug: Placebo tablet
Placebo tablet for oral use, matching DS-5565 tablet
Other Names:
  • Tablet Control
Drug: Placebo capsule
Placebo capsule for oral use, matching pregabalin capsule
Other Names:
  • Capsule Control
Other: Pregabalin
Participants take one pregabalin capsule and one placebo tablet BID
Drug: Placebo tablet
Placebo tablet for oral use, matching DS-5565 tablet
Other Names:
  • Tablet Control
Drug: Pregabalin
Pregabalin capsule for oral use; 75 mg capsule for one week, then 150 mg capsule
Other Names:
  • Other treatment - not comparator
Experimental: DS-5565 15 mg QD
Participants take one each of placebo tablet and capsule in the morning and one placebo capsule in the evening with one DS-5565 tablet once daily (QD)
Drug: Placebo tablet
Placebo tablet for oral use, matching DS-5565 tablet
Other Names:
  • Tablet Control
Drug: Placebo capsule
Placebo capsule for oral use, matching pregabalin capsule
Other Names:
  • Capsule Control
Drug: DS-5565
DS-5565 15 mg QD or BID; tablet for oral use
Other Names:
  • Mirogabalin
Experimental: DS-5565 15 mg BID
Participants take one placebo capsule with one DS-5565 tablet BID
Drug: Placebo capsule
Placebo capsule for oral use, matching pregabalin capsule
Other Names:
  • Capsule Control
Drug: DS-5565
DS-5565 15 mg QD or BID; tablet for oral use
Other Names:
  • Mirogabalin

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline to Week 13 in Average Daily Pain Score (ADPS) Among Participants Receiving DS-5565, Pregabalin, or Placebo
Time Frame: Baseline up to Week 13 postdose
Average daily pain scores (ADPS) reported by the participant that best describes his or her worst pain over the previous 24 hours. A daily pain score has a scale where 0 = no pain to 10 = worst possible pain. Higher scores indicate a worse outcome. For participants with no Week 13 data, the baseline observation was carried forward (BOCF). The mean (multiple imputation estimate) and standard error (multiple imputation) are reported.
Baseline up to Week 13 postdose

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants Who Answered "Much Improved or Better" in Patient Global Impression of Change at Week 13 Receiving DS-5565, Pregabalin, or Placebo
Time Frame: Baseline up to Week 13 postdose
Patient global impression of change (PGIC) on a 7-point categorical scale, where 1 = very much improved and 7 = very much worse. Higher scores indicate worse outcomes. The number of participants with 'much improved or better' status (≤2) is being reported.
Baseline up to Week 13 postdose
Change From Baseline to Week 13 in Average Score on the Fibromyalgia Index Questionnaire (FIQ) in Participants Receiving DS-5565, Pregabalin, or Placebo
Time Frame: Baseline up to Week 13 postdose

The total FIQ score is composed of 10 items, with a maximum possible score of 100. The first item contains 11 questions related to physical functioning and are rated on a 4-point Likert-type scale, where 0 indicates 'always' and 3 indicates 'never'. The overall impact items are rated on a 0-7 scale for the number of days that the patient felt well and the number of days they were unable to work (including housework) because of fibromyalgia symptoms. The symptoms items are rated on visual analog scales (0-10 cm), with higher numbers indicated greater symptomatology. Final scores range from 0 (no impairment) to 10 (maximum impairment), where higher scores indicate worse outcome.

For this outcome, the change in total FIQ score from baseline is being reported. Negative values indicate improvement from baseline in impairment.
Baseline up to Week 13 postdose
Number of Participants Classified As Responders at Week 13 Among Participants Receiving DS-5565, Pregabalin, or Placebo
Time Frame: Week 13 postdose
The ADPS responder rate was defined a priori as the proportion of participants who met the clinically relevant reductions (ie, ≥30% and ≥50%) in ADPS at Week 13 (baseline observation carried forward) compared to Baseline.
Week 13 postdose
Change From Baseline to Week 13 in Multidimensional Fatigue Inventory (MFI-20) General Fatigue Score Among Participants Receiving DS-5565, Pregabalin, or Placebo
Time Frame: Baseline up to Week 13 postdose

MFI is a validated 20-item, self-reported instrument designed to measure fatigue in the following dimensions: general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. The respondent is asked to mark an 'X' in 1 of 5 boxes arranged linearly where 1 is 'Yes, that is true' and 5 is 'No, that is not true.' Each subscale consists of 4 items, 2 indicative for fatigue and 2 contraindicative. For the indicative questions, a high score indicates a high fatigue level and low scores indicate a low fatigue levels. Conversely, for the contraindicative questions a high score indicates a low fatigue level and a low score indicates a high fatigue level. Overall, respondents are rated on a scale of 0 (no fatigue) to 7 (high fatigue).

For this outcome, the change from baseline in MFI-20 general fatigue subscale score is being reported. Negative values indicate an improvement in fatigue.
Baseline up to Week 13 postdose
Change From Baseline to Week 13 in Hospital Anxiety and Depression Scale (HADS) Measure Among Participants Receiving DS-5565, Pregabalin, or Placebo
Time Frame: Baseline up to Week 13 postdose
The HADS questionnaire is a reliable, widely-used self-assessment scale to assess symptoms of anxiety and depression. The instrument consists of 7 questions related to anxiety and 7 related to depression, each rated on a 4-point scale (score of 0 to 3). Scores for anxiety and depression are independently summed to compute HADS-Anxiety and HADS-Depression subscale scores, with ranges from 0 to 21, where higher scores indicate greater severity.
Baseline up to Week 13 postdose
Change From Baseline to Week 13 in Short Form 36 (SF-36) Measure Among Participants Receiving DS-5565, Pregabalin, or Placebo
Time Frame: Baseline up to Week 13 postdose
The SF-36 is a generic health survey that asks 36 questions to measure functional health and well-being from the patient's point of view. The SF-36 provides scores for 8 health domains (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) as well as psychometrically-based physical component summary (PCS) and mental component summary (MCS) scores. Each scale is transformed into a 0-100 scale with each question carrying the same weight. The lower the score indicates more disability (ie, worse outcome).
Baseline up to Week 13 postdose
Change From Baseline to Week 13 in EuroQol Five Dimensions Questionnaire (EQ-5D) Measure Among Participants Receiving DS-5565, Pregabalin, or Placebo
Time Frame: Baseline up to Week 13 postdose

The EQ-5D is an instrument that shows high construct validity and responsiveness in patients with chronic pain and has been used specifically in fibromyalgia. The EQ-5D includes a descriptive section with 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each with a scale that ranges from 0 (no problems) to 5 (extreme problems). These 5 dimensions are combined into an overall health utilities index, and an numeric rating scale (100 mm visual analog scale) that measures perception of overall health, with 0 indicating worst health and 100 representing best imaginable health. A summary index with a maximum total score of 1 can be derived from these five dimensions by conversion with a table of scores. The maximum total score of 1 indicates the best health outcome.

For this outcome, the change from baseline in total EQ-5D score is being reported. Positive values indicate an improvement in health.
Baseline up to Week 13 postdose
Change From Baseline to Week 13 in Average Daily Sleep Interference Score (ADSIS) Among Participants Receiving DS-5565, Pregabalin, or Placebo
Time Frame: Baseline up to Week 13 postdose
Pain-associated sleep interference will be assessed using the Average Daily Sleep Interference Score that utilize electronic daily diaries with an 11-point numeric rating scale (NRS) for pain, ranging from 0 (pain does not interfere with sleep) to 10 (pain completely interferes with sleep, unable to sleep). Higher scores indicate worse outcomes.
Baseline up to Week 13 postdose
Number of Participants Reporting Optimal Sleep at Week 13 on the Medical Outcomes Study (MOS) Sleep Scale Among Participants Receiving DS-5565, Pregabalin, or Placebo
Time Frame: Week 13 postdose
The MOS Sleep Scale is a 12-item questionnaire from which the following subscales were derived: sleep disturbance (4 items), quantity of sleep/optimal sleep (1 item), snoring (1 item), awakening due to shortness of breath or due to headache (1 item), sleep adequacy (2 items), and somnolence (3 items). In addition, values for sleep disturbances index (9 items), optimal sleep scale (1 item), and sleep quantity scale (1 item) were determined. Most subscales range from 0 to 100, where higher scores indicate more of the concept begin measured (eg., higher sleep disturbance scores indicate greater sleep disturbances).
Week 13 postdose
Change From Baseline at Week 13 in the Brief Pain Inventory Short Form (BPI-SF) Measure Among Participants Receiving DS-5565, Pregabalin, or Placebo
Time Frame: Baseline up to Week 13 postdose
The BPI-SF measures pain severity and interference within the past 24 hours. Items are rated on an 11-point NRS from 0 to 10, where 0 indicates does not interfere and 10 indicates completely interferes. Severity score is the average of the responses to the 4 pain intensity items that assess the Worst/Least/Average pain in the last 24 hours and the Pain Right Now. The individual items being reported (using the same scale as noted above) are Severity, General Activity, Mood, Walking Ability, Normal Work, Relations With Other People, Sleep, and Enjoyment of Life. Percentage relief of treatment pain scale ranges from 100% (complete pain relief) to 0% (no pain relief) and higher percentages indicate better outcome. Interference % is the average of responses for General activity, Mood, Walking ability, Normal work, Relations with other people, Sleep, Enjoyment of life where 0% (no interference) to 100% (completely interferes) and negative (ie. lower) percentages indicate better outcomes.
Baseline up to Week 13 postdose
Proportion of Days a Rescue Medication Was Used Among Participants Receiving DS-5565, Pregabalin, or Placebo
Time Frame: Week 1 to Week 13 postdose
Proportion of days with rescue medication intake during the double-blind treatment period equals number of days with rescue medication intake/(date of last study drug administration in the double-blind treatment period) - (date of first study drug administration + 1).
Week 1 to Week 13 postdose

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Daiichi Sankyo, Inc.

Collaborators

Syneos Health

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 16, 2015

Primary Completion (Actual)

January 6, 2017

Study Completion (Actual)

January 12, 2017

Study Registration Dates

First Submitted

July 8, 2014

First Submitted That Met QC Criteria

July 10, 2014

First Posted (Estimate)

July 11, 2014

Study Record Updates

Last Update Posted (Actual)

November 9, 2020

Last Update Submitted That Met QC Criteria

November 5, 2020

Last Verified

November 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • DS5565-A-E310
  • 2013-005162-20 (EudraCT Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

IPD Sharing Time Frame

Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

IPD Sharing Access Criteria

Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

IPD Sharing Supporting Information Type

  • Study Protocol
  • Statistical Analysis Plan (SAP)
  • Clinical Study Report (CSR)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain Associated With Fibromyalgia

Clinical Trials on Placebo tablet

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe